Foscarnet-induced electrolyte abnormalities in a bone marrow transplant patient receiving parental nutrition

Journal of Parenteral and Enteral Nutrition

Volumn 24, Issue 3, 2000, Pages 170-173

  Matarese, L E ^a   Speerhas, R ^a   Seidner, D L ^a   Steiger, E ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMPHOTERICIN B; CEFTAZIDIME; COTRIMOXAZOLE; DEXAMETHASONE; FOSCARNET; FUROSEMIDE; GLUCONATE CALCIUM; HYDROCORTISONE; METHOTREXATE; TACROLIMUS; TIMENTIN; TOBRAMYCIN; VANCOMYCIN;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CLINICAL FEATURE; CYTOMEGALOVIRUS INFECTION; DISEASE COURSE; ELECTROLYTE DISTURBANCE; HUMAN; IMMUNE DEFICIENCY; MALE; PARENTERAL NUTRITION; PRIORITY JOURNAL;

EID: 0033860285     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607100024003170     Document Type: Article

References (29)

1. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation
2. Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: A report from the Working Party for Infectious Disease of the EBMT
3. Foscarnet: A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis
4. Treatment of cytomegalovirus retinitis with trisodium phosphonophormate hexahydrate (foscarnet)
5. Intravenous foscarnet for the treatment of sever cytomegalovirus infection in allograft recipients
6. Phase I-II trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients
7. CMV prophylaxis for foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections
8. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients
9. Foscarnet therapy for cytomegalovirus infection after allogeneic bone marrow transplantation
10. Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis
11. Foscarnet nephrotoxicity: Mechanism, incidence and prevention
12. Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis
13. Foscarnet-induced hypokalemia
14. Foscarnet for treatment of cytomegalovirus infection in bone marrow transplant recipients
15. Reversible inhibition of cytomegalovirus replication by phosphonoformate
16. Foscarnet sodium
17. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy
18. +/Pi cotransport by phosphonoformic acid
19. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism
20. Neurologic sequelae associated with foscarnet therapy
21. Comparison of pharmacokinetics and dynamics of two dosage regiments of foscarnet in AIDS patients with cytomegalovirus retinitis
22. Antiviral effects of phosphonoformate (PFA, foscarnet sodium)
23. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection
24. Foscarnet therapy for acyclovir-resistant herpes simplex virus 1 infection in allogeneic bone marrow transplant recipients
25. Reversible acute renal failure caused by the combined used of foscarnet and cyclosporin in organ transplanted patients
26. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus in patients with AIDS
27. Foscarnet-induced severe hypomagnesemia and other electrolyte disorders
28. Evidence for parathyroid failure in magnesium deficiency